相关实验视频

Updated: Jun 21, 2025

Wet Chemistry and Peptide Immobilization on Polytetrafluoroethylene for Improved Cell-adhesion

Wet Chemistry and Peptide Immobilization on Polytetrafluoroethylene for Improved Cell-adhesion

Published on: August 15, 2016

通过展开延伸改善治疗候选N-TIMP2的循环半衰期

Jason Shirian¹, Alexandra Hockla², Justyna J Gleba²

¹Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, 9190401, Israel.

bioRxiv : the preprint server for biology

|July 9, 2024

概括

PATylation延长了TIMP2 (N-TIMP2) 蛋白结构的N端域的血半衰期. 这种新的方法提高了N-TIMP2的治疗潜力,用于治疗由矩阵金属蛋白酶 (MMP) 驱动的疾病.

科学领域:

生物化学生物化学
药物开发药物开发
蛋白质工程是指蛋白质工程.

背景情况:

矩阵金属蛋白酶 (MMPs) 是癌症等疾病的关键驱动因素,使他们成为药物开发的关键目标.
组织金属蛋白酶抑制剂 (TIMPs) 抑制MMPs,并且由于其有效性和安全性,作为治疗药物表现有前途.
基于TIMP的药物的一个重大挑战是它们的短血半衰期,限制了治疗效果.

研究的目的:

研究PATylation作为一种延长TIMP2 (N-TIMP2) N终端域的血半衰期的方法.
设计,生产和评估PATylated N-TIMP2结构,以改善药物输送和治疗潜力.

主要方法:

设计了两个PATylated N-TIMP2结构 (N-TIMP2-PAT100和N-TIMP2-PAT200) 具有内在展开的100和200氨基酸的尾巴.
评估了PATylated结构的分子量和MMP-9抑制活性.
在小鼠模型中评估了N-TIMP2-PAT200的血半衰期.

主要成果:

两种PATylated N-TIMP2结构的表面分子重量都高于野生型N-TIMP2.
这些结构保留了对MMP-9的显著抑制活性.
与非PATylated变体相比,N-TIMP2-PAT200在小鼠中显著增加了血半衰期.

结论:

PATylation是一种有效的策略,可以延长N-TIMP2的血半衰期,从而提高其治疗潜力.
这种方法提供了诸如遗传编码,单分散和生物降解等优势.
可以将PATylation应用于工程N-TIMP2变体,以有针对性的抑制特定的MMP,帮助开发用于MMP相关疾病的药物.

更多相关视频

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

Constructing Thioether/Vinyl Sulfide-tethered Helical Peptides Via Photo-induced Thiol-ene/yne Hydrothiolation

Constructing Thioether/Vinyl Sulfide-tethered Helical Peptides Via Photo-induced Thiol-ene/yne Hydrothiolation

Published on: August 1, 2018

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...